AIM - AIM Immunotech announces sale of New Brunswick New Jersey facility

AIM ImmunoTech (NYSE:AIM) announces strategic sale of its facility located in New Brunswick, New Jersey for a purchase price of $3.9M. The Company will retain access to space in the New Brunswick facility for activities related to Alferon-N and also intends to lease additional space in a N.J.-based facility suitable for product development and testing. “Our priorities are focused on positioning the Company to advance our clinical programs — especially in oncology and long-COVID — as quickly and efficiently as possible, executing our operational, clinical and regulatory milestones. This strategic transaction should reduce our expenses and save over $1.0 million a year in cash flow. The cash and cash-flow savings will be used to advance our oncology and long-COVID clinical programs.” said Thomas Equels, Chief Executive Officer Recently, the company appointed Dickey IV as CFO.

For further details see:

AIM Immunotech announces sale of New Brunswick, New Jersey facility